⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24587356 | 0.83 | — | — | |
| SCHEMBL12145777 | 0.76 | — | — | |
| SCHEMBL765795 | 0.75 | — | — | |
| SCHEMBL12143874 | 0.74 | — | — | |
| SCHEMBL24868367 | 0.74 | — | — | |
| SCHEMBL345669 | 0.70 | — | — | |
| SCHEMBL14899025 | 0.70 | — | — | |
| SCHEMBL24470876 | 0.68 | — | — | |
| SCHEMBL4186713 | 0.68 | — | — | |
| SCHEMBL14899026 | 0.68 | DPP4 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024124002-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | THIRD HARMONIC BIO, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4269403-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | GT Apeiron Therapeutics Limited (HK) | 2023-11-01 | — | — | EP | disclosed |
| US-11787810-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787810-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230270719-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| US-11584738-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230012262-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| EP-3922634-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20210363147-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-11-25 | — | — | US | disclosed |
| US-20210147429-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| US-10836769-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-20190292187-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2019-09-26 | — | — | US | disclosed |
| US-10328053-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180161307-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20180161307-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2018-06-14 | — | — | US | disclosed |
| WO-2018039531-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2018-03-01 | — | — | WO | disclosed |